LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | A443654 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1178 | 4223 | 0.2791 | -0.0790 |
| SK-BR-3 | OSI-027 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1826 | 4223 | 0.4325 | 0.1507 |
| SK-BR-3 | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 1401 | 3737 | 4223 | 0.8850 | 0.8278 |
| SK-BR-3 | HG-6-64-01 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 3319 | 4223 | 0.7859 | 0.6796 |
| SK-BR-3 | WH-4-025 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3382 | 4223 | 0.8010 | 0.7021 |
| SK-BR-3 | WZ-4-145 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 2283 | 4223 | 0.5406 | 0.3124 |
| SK-BR-3 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1585 | 4223 | 0.3755 | 0.0653 |
| SK-BR-3 | Brivanib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4205 | 4223 | 0.9957 | 0.9936 |
| SK-BR-3 | Buparlisib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1895 | 4223 | 0.4489 | 0.1751 |
| SK-BR-3 | BX-912 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1423 | 4223 | 0.3370 | 0.0076 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1608 | 4223 | 0.3808 | 0.0733 |
| SK-BR-3 | Celastrol | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1875 | 4223 | 0.4440 | 0.1678 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1329 | 4223 | 0.3147 | -0.0257 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 1081 | 4223 | 0.2561 | -0.1135 |
| SK-BR-3 | CHIR-99021 | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4056 | 4223 | 0.9605 | 0.9409 |
| SK-BR-3 | CP724714 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 2441 | 4223 | 0.5782 | 0.3686 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4613 | 4223 | 1.0924 | 1.1383 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3954 | 4223 | 0.9363 | 0.9046 |
| SK-BR-3 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 3946 | 4223 | 0.9345 | 0.9020 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4307 | 4223 | 1.0200 | 1.0300 |
| SK-BR-3 | Dasatinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 3837 | 4223 | 0.9087 | 0.8634 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 2533 | 4223 | 0.5999 | 0.4011 |
| SK-BR-3 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4602 | 4223 | 1.0897 | 1.1343 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 4054 | 4223 | 0.9601 | 0.9403 |
| SK-BR-3 | Foretinib | 0.37 | uM | LJP5 | 72 | hr | 1401 | 1773 | 4223 | 0.4200 | 0.1319 |